Foretinib (GSK1363089): Multikinase ATP-Competitive Inhib...
Foretinib (GSK1363089): Multikinase ATP-Competitive Inhibitor for Cancer Research
Executive Summary: Foretinib (GSK1363089) is a small-molecule ATP-competitive inhibitor that targets multiple receptor tyrosine kinases, including VEGFRs and Met, with IC50 values in the nanomolar range (APExBIO). It suppresses tumor cell proliferation, migration, and invasion across several cancer cell lines under standard in vitro conditions (Schwartz 2022). Foretinib induces G2/M cell cycle arrest and blocks HGF-induced motility. Oral administration in xenograft models leads to significant tumor weight reduction. Proper storage and solubility management are critical for experimental reproducibility.
Biological Rationale
Cancer progression relies on dysregulated cell signaling networks, notably those driven by growth factor receptors. Receptor tyrosine kinases (RTKs) such as VEGFRs, MET (HGFR), and PDGFRs orchestrate angiogenesis, cell proliferation, and metastasis (Schwartz 2022). Targeting these kinases with ATP-competitive inhibitors interrupts aberrant signaling, offering a strategy for controlling tumor growth and dissemination. Foretinib (GSK1363089) was developed to provide broad-spectrum RTK inhibition, addressing redundancy and compensatory activation often observed in cancer models. Its high affinity for VEGFR2 (KDR), Flt-1, Flt-4, MET, Ron, KIT, Flt-3, Tie-2, and PDGFRs enables robust suppression of multiple oncogenic pathways. This approach enhances the reliability of in vitro and in vivo models for preclinical drug evaluation and pathway dissection.
Mechanism of Action of Foretinib (GSK1363089)
Foretinib is a small-molecule inhibitor that competitively binds the ATP-binding pocket of its target kinases. Key targets include VEGFR2 (KDR), Flt-1, Flt-4 (VEGFR3), MET (HGFR), Ron, KIT, Flt-3, PDGFR-α/β, and Tie-2, with IC50 values spanning 0.4–9.6 nM for kinase inhibition in purified enzyme assays at 25°C and physiological pH (APExBIO). In cultured cancer cell lines (e.g., B16F10, PC-3, A549, HT29), Foretinib inhibits cellular MET phosphorylation with IC50 ≈ 21–23 nM. This suppresses HGF-induced cell motility and migration. Cellular phenotypes include induction of G2/M cell cycle arrest and decreased proliferation. The blockade of VEGF and HGF signaling reduces angiogenic and metastatic potential. In vivo, oral dosing at 30 mg/kg reduces tumor burden and metastatic nodules in ovarian cancer xenograft models.
Evidence & Benchmarks
- Foretinib inhibits purified MET, VEGFR2, Flt-1, Flt-4, KIT, Flt-3, PDGFR-α/β, and Tie-2 kinases with IC50s between 0.4–9.6 nM at 25°C in standard kinase buffer (APExBIO).
- In B16F10, PC-3, A549, and HT29 cancer cell lines, Foretinib inhibits cellular MET phosphorylation at IC50 ≈ 21–23 nM under normoxic, serum-supplemented conditions (Schwartz 2022).
- Foretinib treatment leads to significant G2/M cell cycle arrest and reduces proliferation in tumor cells, as measured by flow cytometry and viability assays (Schwartz 2022).
- Oral administration of 30 mg/kg Foretinib in ovarian cancer xenograft mice significantly reduces metastatic nodules and tumor mass compared to vehicle controls (APExBIO).
- Foretinib is soluble at ≥31.65 mg/mL in DMSO but insoluble in water and ethanol, requiring careful stock preparation (APExBIO).
Compared to previous overviews, this article provides detailed quantitative benchmarks and clarifies solubility and storage requirements for Foretinib (GSK1363089).
Applications, Limits & Misconceptions
Foretinib is widely used for:
- Dissecting VEGF and HGF signaling pathways in cancer cell lines.
- Evaluating cell motility and invasion in migration/invasion assays.
- Modeling tumor growth and metastasis in xenograft and metastasis models.
- Screening for multikinase resistance mechanisms.
For practical strategies on robust assay design, see this guide, which this article extends by providing updated benchmarks and clarification on solubility and storage.
For troubleshooting kinase inhibition and comparative selection, see this resource; the current article updates in vivo efficacy and details validated storage protocols.
Common Pitfalls or Misconceptions
- Foretinib is not water or ethanol soluble: Stock solutions must be prepared in DMSO, as solubility <31.65 mg/mL is only confirmed in this solvent (APExBIO).
- Not for diagnostic or clinical use: Foretinib (GSK1363089) is intended for scientific research only and is not approved for therapeutic applications.
- Degradation risk if not stored at -20°C: Stocks should be aliquoted and used promptly to prevent loss of activity.
- Effectiveness is cell context-dependent: Not all cell lines are equally sensitive; efficacy may vary with RTK expression levels.
- Single-agent activity does not preclude resistance: Chronic exposure can select for compensatory kinase signaling and reduced sensitivity.
Workflow Integration & Parameters
Foretinib is supplied by APExBIO as SKU A2974 (product page). For in vitro work, dissolve at ≥31.65 mg/mL in DMSO, make single-use aliquots, and store at -20°C. For cell-based assays, typical working concentrations range from 10–100 nM, with MET inhibition observed at ~21–23 nM. Control for DMSO vehicle effects. For in vivo studies, an oral dose of 30 mg/kg is validated for metastatic inhibition in mouse xenograft models. Monitor for batch-to-batch consistency and avoid repeated freeze-thaw cycles. For best practices in cell viability and cytotoxicity assay setup, see this scenario-driven guide, which this article builds upon by providing more precise dosing and storage recommendations.
Conclusion & Outlook
Foretinib (GSK1363089) is a validated, potent ATP-competitive inhibitor of VEGFR, HGFR (Met), and related kinases. Its nanomolar efficacy in inhibiting tumor cell growth and metastasis makes it a powerful reagent for preclinical cancer research. Proper handling, solubility management, and selection of context-appropriate models are essential for reproducible results. Future studies may explore Foretinib’s role in combination therapies and resistance modeling. For ordering and further documentation, consult the A2974 kit from APExBIO.